Palisade Bio (NASDAQ:PALI) Issues Quarterly Earnings Results

by · The Cerbat Gem

Palisade Bio (NASDAQ:PALI – Get Free Report) posted its earnings results on Tuesday. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by ($0.01), FiscalAI reports.

Palisade Bio Stock Down 1.0%

Shares of NASDAQ:PALI traded down $0.02 during midday trading on Tuesday, reaching $1.92. The company had a trading volume of 1,798,674 shares, compared to its average volume of 4,294,480. The business’s 50 day moving average price is $1.98 and its 200 day moving average price is $1.92. The stock has a market cap of $321.45 million, a PE ratio of -0.91 and a beta of 1.52. Palisade Bio has a 1-year low of $0.53 and a 1-year high of $2.86.

Institutional Trading of Palisade Bio

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC acquired a new stake in shares of Palisade Bio in the fourth quarter valued at about $28,000. Creek Drive Management Group LLC acquired a new stake in shares of Palisade Bio in the fourth quarter valued at about $723,000. XTX Topco Ltd increased its position in shares of Palisade Bio by 53.8% in the fourth quarter. XTX Topco Ltd now owns 21,669 shares of the company’s stock valued at $51,000 after acquiring an additional 7,584 shares during the last quarter. Ikarian Capital LLC acquired a new stake in shares of Palisade Bio in the fourth quarter valued at about $646,000. Finally, Squadron Capital Management LLC acquired a new position in Palisade Bio during the fourth quarter worth approximately $10,575,000. Institutional investors and hedge funds own 11.79% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on PALI. Wall Street Zen upgraded Palisade Bio from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Wolfe Research began coverage on Palisade Bio in a report on Thursday, April 9th. They set an “outperform” rating and a $7.00 target price on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Palisade Bio in a report on Thursday, January 22nd. Stifel Nicolaus began coverage on Palisade Bio in a report on Wednesday, February 25th. They issued a “buy” rating and a $5.00 price target on the stock. Finally, HC Wainwright began coverage on Palisade Bio in a report on Thursday, March 26th. They issued a “buy” rating and a $7.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.20.

Read Our Latest Research Report on PALI

About Palisade Bio

(Get Free Report)

Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.

The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.

Recommended Stories